Issued: London, UK

Sales of £8.6 billion -8% AER, -3% CER (Pro-forma -5% CER*)
Total EPS 25.0p, -20% AER, -9% CER; Adjusted EPS 35.6p, -8% AER, +1% CER

Attachments

  • Original document
  • Permalink

Disclaimer

GSK - GlaxoSmithKline plc published this content on 28 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2020 12:09:05 UTC